Stockreport

Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Carboplatin in Patients with Advanced or Metastatic Solid Tumors

Deciphera Pharmaceuticals, Inc.  (DCPH) 
Last deciphera pharmaceuticals, inc. earnings: 3/9 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: deciphera.com/investor-relations
PDF - Rebastinib is a Potent and Selective Inhibitor of the TIE2 kinase, the Receptor for Angiopoietins, an Important Family of Vascular Growth Factors Invol [Read more]